Allergy Therapeutics ( (GB:AGY) ) has shared an update.
Allergy Therapeutics reported a financial turnaround with a £1.9 million operating profit before R&D and other costs, and a 4% revenue growth on a constant currency basis for the six months ended December 2024. The company has strengthened its financial position with a cash reserve of £21.7 million and has made significant progress in its clinical programs, including the submission of a Marketing Authorisation Application for Grass MATA MPL in Germany and promising interim results from its VLP Peanut allergy vaccine trial. These developments position the company to advance its strategic priorities and potentially transform patient care in allergy treatment.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology company specializing in allergy vaccines. The company focuses on developing and marketing innovative treatments for allergies, with a particular emphasis on short-course allergen-specific immunotherapies.
YTD Price Performance: -0.31%
Average Trading Volume: 383,919
Technical Sentiment Signal: Sell
Current Market Cap: £308.9M
For a thorough assessment of AGY stock, go to TipRanks’ Stock Analysis page.